Xavier Luria

Biography

Independent consultant on Drug Development and Drug Regulation, he founded DDR (Drug Development and Regulation), located in Barcelona and London, where he is the Chair and Senior Consultant. Xavier is also a member of the Kinesys Consulting Ltd Expert Advisory Board where he advises on a range of Kinesys projects. He was Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) during 2005-2012, and previously held leadership positions in the biopharmaceutical industry for more than eighteen years, covering international clinical development, pharmacovigilance, biostatistics and medical affairs. In addition to Dr. Luria’s specialty in internal medicine, pharmaceutical medicine and biostatistics (University Autonomous Barcelona), he has developed expertise in several specific therapeutic areas, carried out postgraduate qualification in clinical pharmacology, drug development and regulation (Tufts University School of Medicine, Boston), he is a recognized expert on regulatory systems and benefit-risk assessment (modelling, development and methodologies) and has been lecturer at the UCSF. Furthermore, he is professor of Regulation of Life Science Industry at the IE Business School and at an IFAPP-King’s College Postgraduate Course and lecturer at several other academic institutions in Europe and USA. He is also member of the European Advisory Board of RAPS. He is currently member of the advisory board of several biopharmaceutical and medical devices companies and serves as consultant and regulatory service provider to many others in Europe, Japan, US, Australia, Israel and Latin America. Independent consultant on Drug Development and Drug Regulation, he founded DDR (Drug Development and Regulation), located in Barcelona and London, where he is the Chair and Senior Consultant. Xavier is also a member of the Kinesys Consulting Ltd Expert Advisory Board where he advises on a range of Kinesys projects. He was Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) during 2005-2012, and previously held leadership positions in the biopharmaceutical industry for more than eighteen years, covering international clinical development, pharmacovigilance, biostatistics and medical affairs. In addition to Dr. Luria’s specialty in internal medicine, pharmaceutical medicine and biostatistics (University Autonomous Barcelona), he has developed expertise in several specific therapeutic areas, carried out postgraduate qualification in clinical pharmacology, drug development and regulation (Tufts University School of Medicine, Boston), he is a recognized expert on regulatory systems and benefit-risk assessment (modelling, development and methodologies) and has been lecturer at the UCSF. Furthermore, he is professor of Regulation of Life Science Industry at the IE Business School and at an IFAPP-King’s College Postgraduate Course and lecturer at several other academic institutions in Europe and USA. He is also member of the European Advisory Board of RAPS. He is currently member of the advisory board of several biopharmaceutical and medical devices companies and serves as consultant and regulatory service provider to many others in Europe, Japan, US, Australia, Israel and Latin America.

Research Interest

Pharmaceutical Sciences